Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2004 Jul;48(7):2771-7.
doi: 10.1128/AAC.48.7.2771-2777.2004.

In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms

Laurel S Almer  1 , Jennifer B Hoffrage, Erika L Keller, Robert K Flamm, Virginia D Shortridge
Affiliations
Comparative Study

In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms

Laurel S Almer et al. Antimicrob Agents Chemother. 2004 Jul.

Abstract

In vitro activities of ABT-492, ciprofloxacin, levofloxacin, trovafloxacin, moxifloxacin, gatifloxacin, and gemifloxacin were compared. ABT-492 was more potent against quinolone-susceptible and -resistant gram-positive organisms, had activity similar to that of ciprofloxacin against certain members of the family Enterobacteriaceae, and had comparable activity against quinolone-susceptible, nonfermentative, gram-negative organisms. Bactericidal activity of ABT-492 was also evaluated.

PubMed Disclaimer

References

    1. Almer, L. S., V. D. Shortridge, A. M. Nilius, J. M. Beyer, N. B. Soni, M. H. Bui, G. G. Stone, and R. K. Flamm. 2002. Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus. Diagn. Microbiol. Infect. Dis. 43:225-232. - PubMed
    1. Biedenbach, D. J., and R. N. Jones. 2000. Fluoroquinolone-resistant Haemophilus influenzae: frequency of occurrence and analysis of confirmed strains in the SENTRY Antimicrobial Surveillance Program (North and Latin America). Diagn. Microbiol. Infect. Dis. 36:255-259. - PubMed
    1. Blondeau, J. M., R. Laskowski, J. Bjarnason, and C. Stewart. 2000. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4,151 gram-negative and gram-positive organisms. Int. J. Antimicrob. Agents 14:45-50. - PubMed
    1. Brueggemann, A. B., S. L. Coffman, P. Rhomberg, H. Huynh, L. Almer, A. Nilius, R. Flamm, and G. V. Doern. 2002. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob. Agents Chemother. 46:680-688. - PMC - PubMed
    1. Dalhoff, A., and F. J. Schmitz. 2003. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur. J. Clin. Microbiol. Infect. Dis. 22:203-221. - PubMed

Publication types

MeSH terms

LinkOut - more resources